Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Knight Therapeutics launches WYNZORA...
Business product launch

Knight Therapeutics launches WYNZORA in Canada

Analysis based on 7 articles · First reported Aug 20, 2026 · Last updated Aug 20, 2026

Sentiment
20
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The launch is expected to modestly boost Knight Therapeutics' Canadian revenue and strengthen its dermatology portfolio. It may also increase market share in the Canadian psoriasis treatment market, though competition from existing therapies could limit significant financial impact.

Pharmaceuticals Biotechnology Healthcare
Event Summary

Knight Therapeutics Inc. announced the launch of WYNZORA, a topical cream for psoriasis vulgaris, in Canada. WYNZORA is a fixed-dose combination of calcipotriol and betamethasone dipropionate, developed by MC2 Therapeutics using its PAD Technology platform. Knight obtained Canadian rights through its June 2025 acquisition of Paladin Pharma Inc., which had licensed the product from MC2 in November 2024. Canada — Health Canada approved WYNZORA in December 2025, and the product is now commercially available in Canada. The launch expands Knight's Canadian portfolio and provides a new treatment option for the estimated 1 million Canadians with psoriasis.

Key Actions
100 Knight Therapeutics launched
80 Knight Therapeutics acquired assets Paladin Pharma Inc.
70 Canada — Health Canada approved Knight Therapeutics
60 Paladin Pharma Inc. entered license agreement MC2 Therapeutics
Entities Involved
stock
Knight Therapeutics
Knight Therapeutics is the primary actor, launching WYNZORA in Canada, which expands its product portfolio and may drive revenue growth.
Importance 100.0 Sentiment 30.0
priv
MC2 Therapeutics
MC2 Therapeutics is the developer and licensor of WYNZORA; the Canadian launch expands its product's global reach and validates its PAD Technology platform.
Importance 80.0 Sentiment 20.0
cnt
Canada
Canada is the market where WYNZORA is launched, providing a new treatment option for psoriasis patients.
Importance 60.0 Sentiment 10.0
govactor
Canada — Health Canada
Canada — Health Canada approved WYNZORA in December 2025, a regulatory prerequisite for the launch.
Importance 50.0 Sentiment 0.0
priv
Paladin Pharma Inc.
Paladin Pharma Inc. previously held Canadian rights to WYNZORA; its assets were acquired by Knight, enabling the launch.
Importance 40.0 Sentiment 10.0
per
Samira Sakhia
Samira Sakhia, CEO of Knight Therapeutics, announced the launch and highlighted its strategic importance.
Importance 30.0 Sentiment 0.0
cnt
United States
The United States was the first market where WYNZORA was approved, but is not directly affected by this Canadian launch.
Importance 20.0 Sentiment 0.0
exch
Toronto Stock Exchange
Knight Therapeutics is listed on the Toronto Stock Exchange; the launch may influence its stock price.
Importance 20.0 Sentiment 10.0
govactor
United States — Food and Drug Administration
The FDA approved WYNZORA in the US in 2020, but is not directly involved in the Canadian launch.
Importance 10.0 Sentiment 0.0
cnt
United Kingdom
The United Kingdom hosts MC2's R&D operations, but is not directly impacted by the launch.
Importance 10.0 Sentiment 0.0
cnt
Australia
Australia previously approved WYNZORA, but is not directly affected by the Canadian launch.
Importance 10.0 Sentiment 0.0
alliance
European Union
The European Union approved WYNZORA in 2021, but is not directly impacted by this event.
Importance 10.0 Sentiment 0.0
cnt
Denmark
Denmark is the headquarters of MC2 Therapeutics, the product developer.
Importance 10.0 Sentiment 0.0
Relationships
Knight Therapeutics related ↔ United States — Food and Drug Administration
Canada related ↔ Canada — Health Canada
Canada trade rivals ↔ United States Canada views the United States as a strained partner and trade rival, facing significant tariffs and renegotiation of tr
Canada related ↔ Toronto Stock Exchange
Canada related ↔ United States — Food and Drug Administration
Canada related ↔ United Kingdom
Canada — Health Canada related ↔ United States
Canada — Health Canada related ↔ United States — Food and Drug Administration
Canada — Health Canada related ↔ United Kingdom
United States related ↔ Toronto Stock Exchange
United States related ↔ United States — Food and Drug Administration
United States allies ↔ United Kingdom The United States considers the United Kingdom a vital defense ally and significant economic partner, relying on its str
United States — Food and Drug Administration related ↔ United Kingdom
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.